Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts less than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Orchid Pharma reported standalone revenue of Rs. 81,133 lakhs for FY2026, down 12% from Rs. 92,193 lakhs in FY2025. Standalone profit before tax declined significantly to Rs. 4,521 lakhs from Rs. 10,648 lakhs in the previous year, a drop of about 57%. The auditors issued an unmodified opinion on standalone results but a qualified opinion on consolidated results due to three US subsidiaries (Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals Inc.) whose financials remain unaudited, with assets of Rs. 386 lakhs and nil revenue. The company completed acquisitions of Allecra Therapeutics entities in Germany and France during the year, gaining full ownership of the Enmetazobactam antibiotic molecule. A petition for amalgamation with Dhanuka Laboratories Limited is pending before NCLT.
The revenue and profit decline may concern investors, while the qualified audit opinion on consolidated results signals potential transparency issues regarding US subsidiary financials. The pending amalgamation with Dhanuka Laboratories could be a positive catalyst if approved.